Canine Gastric Ulceration: Diagnosis and Management

Canine gastric ulceration involves erosion of the gastric mucosa that can progress to hemorrhage, perforation, or obstruction. This article provides veterinarians with evidence-based guidance on pathophysiology, diagnostic methods, and management strategies for gastric ulceration in dogs. The condition arises from an imbalance between aggressive factors (acid, pepsin, bile acids) and protective mechanisms (mucus, bicarbonate, blood flow, prostaglandins). Common causes include nonsteroidal anti-inflammatory drug (NSAID) administration, hepatic disease, stress, mast cell tumors, and gastric neoplasia. Diagnosis relies on endoscopic visualization with biopsy confirmation, supported by clinical signs, hematologic findings, and fecal occult blood testing. Management focuses on removing the inciting cause, suppressing gastric acid secretion, providing mucosal protection, and surgical intervention when perforation or uncontrolled hemorrhage occurs.

At a Glance

Pathophysiology and Etiology

Mechanisms of Mucosal Injury

Gastric mucosal integrity depends on a balance between aggressive factors and protective mechanisms. Acid and pepsin secretion, bile reflux, and ischemia represent primary aggressive forces. Protective factors include the mucus-bicarbonate barrier, epithelial cell turnover, mucosal blood flow, and endogenous prostaglandin synthesis. Disruption of this balance leads to mucosal erosion and ulceration.

NSAID-induced gastropathy occurs through two mechanisms. Topical injury results from direct contact with the gastric mucosa, while systemic inhibition of cyclooxygenase-1 (COX-1) reduces prostaglandin synthesis. Prostaglandins normally maintain mucosal blood flow, stimulate mucus and bicarbonate secretion, and promote epithelial cell turnover. Their suppression compromises these protective functions, making the mucosa vulnerable to acid injury.

Hepatic disease contributes to ulcer formation through multiple pathways. Reduced hepatic metabolism of gastrin and histamine increases gastric acid secretion. Portal hypertension alters gastric mucosal blood flow. Endotoxemia from hepatic failure can cause direct mucosal damage. The association between hepatic disease and gastric ulceration has been recognized in clinical practice, as described in the Merck Veterinary Manual.

Stress-related mucosal injury occurs in critically ill patients. Reduced splanchnic perfusion, ischemia-reperfusion injury, and systemic inflammation compromise mucosal defenses. This mechanism parallels stress ulceration described in human medicine.

Common Etiologies

NSAID administration represents the most common identifiable cause of canine gastric ulceration. Dogs receiving NSAIDs for osteoarthritis or postoperative pain management are at increased risk. Risk factors include high doses, concurrent corticosteroid use, preexisting renal or hepatic disease, and advanced age.

Gastric neoplasia, particularly adenocarcinoma and lymphoma, can present with ulceration. Neoplastic infiltration disrupts normal mucosal architecture and may outgrow its blood supply, leading to necrosis and ulcer formation. Gastric intravascular lymphoma has been reported as a rare cause of gastric ulceration in dogs, as documented in the Journal of the American Animal Hospital Association.

Mast cell tumors, especially those with visceral involvement, release histamine that stimulates gastric acid secretion through H2 receptors on parietal cells. This excessive acid production overwhelms mucosal defenses and causes ulceration.

Hepatic disease, including cirrhosis, portosystemic shunts, and acute hepatic failure, predisposes to ulcer formation. The mechanisms involve altered hormone metabolism, portal hypertension, and systemic effects of liver dysfunction.

Other causes include uremia from renal failure, hypoadrenocorticism, pancreatitis, and foreign body ingestion. Idiopathic cases occur when no underlying cause is identified after thorough diagnostic evaluation.

Clinical Presentation and Physical Examination

History and Signalment

Obtain a complete history including medication administration, particularly NSAIDs and corticosteroids. Document the duration and dosage of any NSAID therapy. Ask about access to toxins, foreign bodies, and dietary indiscretion. Note any history of vomiting, its frequency, character, and relationship to eating. Inquire about stool color, consistency, and frequency.

Signalment may provide clues to underlying causes. Young dogs with acute onset of signs may have toxin exposure or foreign body ingestion. Older dogs with chronic vomiting and weight loss raise suspicion for neoplasia. Breeds predisposed to hepatic disease or mast cell tumors warrant specific consideration.

Physical Examination Findings

Perform a complete physical examination with emphasis on the following parameters:

• Mucous membrane color: Pale membranes suggest anemia from blood loss. Icterus indicates hepatic disease or hemolysis.
• Hydration status: Assess skin turgor and mucous membrane moisture. Dehydration occurs from fluid loss through vomiting.
• Abdominal palpation: Gently palpate the cranial abdomen. Pain or guarding may indicate deep ulceration or perforation. Palpable masses suggest neoplasia.
• Rectal examination: Evaluate fecal color and consistency. Melena appears as dark, tarry, sticky feces. Perform fecal occult blood testing if visible blood is absent.
• Body condition: Weight loss indicates chronic disease or malignancy.
• Cardiac and respiratory assessment: Tachycardia and tachypnea may indicate hypovolemia or pain.

Record all findings in the medical record with specific descriptions instead of subjective terms. Document the presence or absence of each sign.

Diagnostic Approach

Initial Laboratory Evaluation

Perform a complete blood count, serum biochemistry profile, and urinalysis in all suspected cases. These tests identify anemia, evaluate organ function, and screen for underlying diseases.

Complete blood count findings may include:

• Regenerative anemia: Indicates acute blood loss with appropriate bone marrow response
• Nonregenerative anemia: Suggests chronic disease or concurrent bone marrow disorder
• Thrombocytopenia: May indicate disseminated intravascular coagulation or immune-mediated disease
• Neutrophilia: Reflects inflammation or stress response

Serum biochemistry abnormalities may include:

• Elevated liver enzymes: Suggests hepatic disease as underlying cause
• Decreased albumin: Indicates protein-losing enteropathy or chronic liver disease
• Elevated blood urea nitrogen and creatinine: May indicate renal failure or prerenal azotemia from dehydration
• Hypoglycemia: Can occur with hepatic failure or sepsis

Urinalysis helps differentiate prerenal from renal azotemia and identifies urinary tract infection that may complicate management.

Fecal Occult Blood Testing

Fecal occult blood testing detects hemoglobin in feces when visible blood is absent. This test supports the diagnosis of gastrointestinal bleeding but does not localize the source. False-positive results occur with dietary hemoglobin from meat-based diets. False-negative results occur with intermittent bleeding or lesions distal to the stomach.

Perform testing on three separate fecal samples collected on consecutive days to improve sensitivity. Document the diet being fed at the time of testing. Consider withholding meat-based diets for 72 hours before testing if clinically appropriate.

Abdominal Imaging

Survey abdominal radiographs may identify:

• Gastric dilation or abnormal gas patterns
• Mass lesions displacing surrounding organs
• Free abdominal gas indicating perforation
• Hepatic or splenic abnormalities

Abdominal ultrasound provides superior evaluation of gastric wall thickness and layering. Ultrasonographic findings suggestive of ulceration include:

• Focal or diffuse gastric wall thickening
• Loss of normal wall layering
• Echogenic mucosal surface
• Perigastric fluid or fat changes indicating inflammation

Ultrasound also evaluates the liver, spleen, pancreas, and lymph nodes for concurrent disease. Guided fine-needle aspiration of mass lesions or abnormal lymph nodes may provide cytologic diagnosis.

Endoscopic Examination

Upper gastrointestinal endoscopy remains the gold standard for diagnosing gastric ulceration. Endoscopy allows direct visualization of the gastric mucosa, assessment of ulcer characteristics, and biopsy collection for histopathology.

Perform endoscopy under general anesthesia with the patient positioned in left lateral recumbency. Insufflate the stomach with air to visualize the entire mucosal surface. Examine the esophagus, lower esophageal sphincter, gastric cardia, fundus, body, antrum, and pylorus. Retroflex the endoscope to view the cardia from below.

Document the following ulcer characteristics:

• Location: Fundus, body, antrum, pylorus
• Number: Single or multiple
• Size: Measure in millimeters
• Depth: Superficial erosion versus deep ulcer
• Appearance: Clean base, adherent clot, visible vessel, active bleeding
• Margins: Smooth, raised, irregular, or undermined
• Surrounding mucosa: Normal, erythematous, edematous, or friable

Biopsy the ulcer margins and surrounding mucosa. Submit samples for histopathology to differentiate benign from malignant lesions. Biopsy the gastric body and antrum regardless of ulcer location to evaluate for gastritis or Helicobacter infection.

Histopathologic Evaluation

Histopathology of gastric biopsies provides definitive diagnosis of the underlying mucosal pathology. Findings may include:

• Chronic gastritis with mucosal erosion
• Eosinophilic gastritis
• Lymphocytic-plasmacytic gastritis
• Gastric neoplasia (adenocarcinoma, lymphoma, leiomyosarcoma)
• Mast cell infiltration

Special stains may identify Helicobacter organisms or other infectious agents. Immunohistochemistry helps classify neoplasms when routine histopathology is inconclusive.

Management Strategies

Stabilization and Supportive Care

Patients with active hemorrhage or hemodynamic instability require immediate stabilization before diagnostic procedures. Establish intravenous access and administer crystalloid fluids to correct hypovolemia. Monitor packed cell volume and total solids to guide fluid therapy and transfusion decisions.

Blood transfusion may be necessary for patients with severe anemia (packed cell volume below 20% or clinical signs of inadequate oxygen delivery). Administer fresh whole blood, packed red blood cells, or other blood products as indicated.

Antiemetic therapy reduces vomiting and associated fluid losses. Maropitant, a neurokinin-1 receptor antagonist, provides effective antiemetic action without affecting gastric acid secretion. Metoclopramide may be used but has prokinetic effects that could theoretically increase gastric motility in the presence of ulceration.

Discontinuation of Inciting Agents

Discontinue all NSAIDs immediately in patients with suspected or confirmed gastric ulceration. This includes both prescription and over-the-counter products. Document the discontinuation in the medical record and provide written instructions to the owner.

If analgesia is required, consider alternative pain management strategies. Opioids (tramadol, buprenorphine, fentanyl) provide analgesia without gastric mucosal injury. Acetaminophen may be used in dogs at appropriate doses but is contraindicated in cats. Gabapentin and amantadine offer adjunctive pain management options.

Corticosteroids should also be discontinued or tapered if possible. The combination of NSAIDs and corticosteroids significantly increases ulcer risk.

Acid Suppression Therapy

Gastric acid suppression promotes ulcer healing by reducing the aggressive environment. Proton pump inhibitors (PPIs) provide the most effective acid suppression by irreversibly binding the hydrogen-potassium ATPase pump in parietal cells.

Omeprazole is the most commonly used PPI in veterinary medicine. It requires acidic pH for activation and should be administered on an empty stomach, ideally 30 to 60 minutes before feeding. The drug undergoes hepatic metabolism and has a relatively short half-life in dogs, requiring twice-daily administration for consistent acid suppression.

Alternative PPIs include pantoprazole and esomeprazole. These may be administered intravenously in patients unable to take oral medications. Intravenous formulations provide rapid and reliable acid suppression.

H2-receptor antagonists (famotidine, ranitidine, cimetidine) provide less consistent acid suppression than PPIs. They competitively block histamine at the H2 receptor on parietal cells. Tolerance develops with prolonged use, reducing their efficacy over time. Famotidine is preferred due to fewer drug interactions compared to cimetidine.

Mucosal Protectants

Sucralfate forms a protective barrier over ulcerated mucosa. It binds to exposed protein at the ulcer base, creating a physical barrier against acid, pepsin, and bile. Sucralfate also stimulates local prostaglandin synthesis and growth factor production.

Administer sucralfate as a slurry on an empty stomach. Separate administration from other oral medications by at least two hours because sucralfate can bind and reduce absorption of other drugs. The medication is excreted unchanged in feces.

Misoprostol is a synthetic prostaglandin E1 analog that replaces endogenous prostaglandins suppressed by NSAIDs. It stimulates mucus and bicarbonate secretion, maintains mucosal blood flow, and promotes epithelial cell turnover. Misoprostol is specifically indicated for NSAID-induced gastropathy.

Administer misoprostol with food to reduce gastrointestinal side effects. The drug may cause diarrhea, abdominal cramping, and uterine contractions. It is contraindicated in pregnant animals due to abortifacient properties.

Surgical Intervention

Surgical intervention is indicated for:

• Perforated gastric ulcer with septic peritonitis
• Uncontrolled hemorrhage despite medical management
• Large or deep ulcers at risk of perforation
• Gastric outflow obstruction from ulcer-related scarring
• Neoplastic ulcers requiring resection

Perform exploratory laparotomy with careful abdominal exploration. Identify the ulcer location and assess for perforation. Resect the affected gastric wall with appropriate margins. Submit resected tissue for histopathology.

Postoperative management includes continued acid suppression, nutritional support, and monitoring for complications. Gastric decompression through a nasogastric tube may be necessary in the immediate postoperative period.

Monitoring and Follow-up

Clinical Response Assessment

Monitor patients daily for resolution of clinical signs. Document the frequency and character of vomiting, appetite, and fecal color. Improvement typically occurs within 48 to 72 hours of initiating appropriate therapy.

Serial packed cell volume measurements assess ongoing blood loss. A stable or increasing packed cell volume indicates hemorrhage control. Continued decline suggests ongoing bleeding requiring further intervention.

Repeat Endoscopy

Repeat endoscopy after 14 to 21 days of therapy evaluates ulcer healing. Complete healing with reepithelialization confirms appropriate response. Persistent or worsening ulcers require further investigation for underlying causes.

Biopsy healed or healing ulcers to rule out neoplasia if initial biopsies were nondiagnostic. Consider additional diagnostic tests based on histopathologic findings.

Long-term Management

Patients with resolved ulcers require management of underlying conditions to prevent recurrence. This may include:

• Avoiding NSAIDs in patients with NSAID-induced gastropathy
• Managing hepatic disease with appropriate medical therapy
• Treating mast cell tumors with surgery, chemotherapy, or both
• Monitoring for recurrence in patients with idiopathic ulcers

Provide owners with written instructions regarding medication administration, dietary recommendations, and signs requiring veterinary attention.

Common Failure Patterns

Incomplete Ulcer Healing

Failure of ulcer healing despite appropriate therapy suggests persistent underlying cause or incorrect diagnosis. Common reasons include:

• Continued NSAID or corticosteroid administration
• Undiagnosed neoplasia
• Inadequate acid suppression
• Poor owner compliance with medication administration

Reevaluate the patient with repeat endoscopy and biopsy. Consider additional diagnostic tests for underlying diseases.

Recurrent Ulceration

Recurrent ulcers after initial healing indicate ongoing mucosal injury. Investigate for:

• Intermittent NSAID use by the owner
• Development of hepatic disease
• Progression of mast cell disease
• Gastrinoma or other neuroendocrine tumor

Measure serum gastrin levels if gastrinoma is suspected. Perform abdominal ultrasound to evaluate for pancreatic or duodenal masses.

Perforation

Gastric perforation represents a life-threatening complication. Clinical signs include acute onset of severe abdominal pain, vomiting, fever, and cardiovascular collapse. Abdominal radiographs may show free gas. Emergency surgical intervention is required.

Professional Escalation Criteria

Urgent Referral Indications

Refer patients to a veterinary internal medicine specialist or emergency facility when:

• Active hemorrhage persists despite medical management
• Packed cell volume continues to decline after transfusion
• Perforation is suspected based on clinical signs or imaging
• Gastric outflow obstruction develops
• Endoscopic biopsy reveals neoplasia requiring specialized management

Routine Referral Indications

Consider referral when:

• Initial endoscopic evaluation is not available in general practice
• Ulcers fail to heal after 14 to 21 days of appropriate therapy
• Underlying cause remains unidentified after thorough diagnostic evaluation
• Surgical resection is required for large or complicated ulcers

Practical Decision Framework for Canine Gastric Ulcer Management

Risk Stratification at Initial Presentation

A structured decision framework helps veterinarians triage patients based on clinical severity and underlying risk factors. This framework uses readily available clinical parameters to guide initial management decisions and escalation timing.

Low Risk Category Patients with mild clinical signs, stable vital parameters, and no evidence of active hemorrhage fall into the low risk category. Criteria include intermittent vomiting without visible blood, normal mucous membrane color, packed cell volume above 35%, and stable cardiovascular parameters. These patients may undergo diagnostic evaluation on an outpatient basis with close monitoring. Begin acid suppression therapy and schedule endoscopy within 24 to 48 hours.

Moderate Risk Category Patients with persistent vomiting, melena, or mild anemia (packed cell volume 25% to 35%) require hospitalization for initial stabilization. Administer intravenous fluids, begin acid suppression therapy, and perform diagnostic testing including complete blood count, serum biochemistry, and abdominal ultrasound. Schedule endoscopy within 12 to 24 hours depending on patient stability.

High Risk Category Patients with hematemesis, severe anemia (packed cell volume below 25%), hemodynamic instability, or suspected perforation require emergency stabilization. Establish intravenous access, administer crystalloid fluids, and prepare for blood transfusion if indicated. Perform abdominal imaging to evaluate for perforation. Emergency endoscopy or surgical exploration may be necessary based on patient response to initial therapy.

Treatment Algorithm Based on Etiology

The underlying cause of gastric ulceration directs specific management decisions beyond general acid suppression and mucosal protection.

NSAID-Induced Ulceration Algorithm Discontinue all NSAIDs immediately. Document the specific NSAID, dose, duration, and concurrent medications. Begin omeprazole at 1 mg/kg orally every 12 hours on an empty stomach. Add sucralfate at 0.5 to 1 gram orally every 8 to 12 hours, separated from omeprazole by at least two hours. Consider misoprostol at 2 to 5 mcg/kg orally every 8 to 12 hours with food if ulceration is severe or recurrent. Provide alternative analgesia using opioids or gabapentin. Schedule repeat endoscopy in 14 to 21 days to document healing.

Hepatic Disease-Associated Ulceration Algorithm Address the underlying hepatic condition concurrently with ulcer management. Begin omeprazole at 1 mg/kg orally every 12 hours. Add sucralfate for mucosal protection. Avoid medications requiring extensive hepatic metabolism when possible. Monitor liver enzymes, bilirubin, and albumin throughout treatment. Consider lactulose and dietary modification for hepatic encephalopathy if present. The prognosis depends on hepatic disease severity and response to therapy.

Neoplasia-Associated Ulceration Algorithm Obtain definitive histopathologic diagnosis through endoscopic biopsy. Begin omeprazole and sucralfate for symptomatic management. Consult with a veterinary oncologist regarding surgical resection, chemotherapy, or radiation therapy based on tumor type and stage. Surgical resection may be curative for localized gastric adenocarcinoma or leiomyosarcoma. Lymphoma may respond to chemotherapy with adjunctive acid suppression.

Stress-Related Ulceration Algorithm Address the underlying critical illness while providing gastric protection. Begin omeprazole intravenously if oral administration is not possible. Maintain adequate tissue perfusion through fluid therapy and vasopressor support if needed. Provide nutritional support through enteral feeding when gastrointestinal function permits. Monitor for signs of gastrointestinal bleeding including serial packed cell volume measurements and fecal occult blood testing.

Record System for Ulcer Monitoring

A standardized record system improves documentation consistency and facilitates treatment response assessment. Maintain the following parameters in the medical record.

Daily Monitoring Log Record the following parameters each day during hospitalization:

• Vomiting episodes: Number and character (blood, bile, food, foam)
• Fecal character: Color, consistency, frequency
• Appetite: Percentage of offered food consumed
• Packed cell volume and total solids
• Mucous membrane color
• Abdominal pain score (0 = none, 1 = mild on palpation, 2 = moderate, 3 = severe)
• Heart rate and respiratory rate
• Body weight

Medication Administration Record Document each medication dose, route, time, and any adverse effects. Note the timing of omeprazole administration relative to feeding. Record sucralfate administration times and separation from other oral medications.

Endoscopy Findings Documentation Create a standardized form for recording endoscopic findings including:

• Ulcer location using a gastric map diagram
• Number of ulcers
• Size in millimeters for each ulcer
• Depth classification (superficial erosion, deep ulcer, perforation)
• Appearance (clean base, adherent clot, visible vessel, active bleeding)
• Biopsy site locations
• Photographs of each ulcer

Treatment Response Assessment Evaluate treatment response at defined intervals:

• Day 3: Assess clinical improvement in vomiting, appetite, and fecal character
• Day 7: Repeat packed cell volume and serum biochemistry
• Day 14 to 21: Repeat endoscopy with biopsy to document healing
• Day 30: Final clinical assessment and long-term management plan

Troubleshooting Method for Poor Treatment Response

When patients fail to improve within 72 hours of initiating appropriate therapy, use the following systematic troubleshooting approach.

Step 1: Verify Medication Administration Confirm that the owner or hospital staff is administering medications correctly. Omeprazole requires administration on an empty stomach 30 to 60 minutes before feeding. Sucralfate must be separated from other oral medications by at least two hours. Misoprostol should be given with food to reduce gastrointestinal side effects. Check that doses are appropriate for the patient's current body weight.

Step 2: Reassess Underlying Cause Review the initial diagnostic findings for missed underlying causes. Consider additional testing including serum gastrin levels, abdominal ultrasound, or advanced imaging. Evaluate for concurrent diseases such as renal failure, hypoadrenocorticism, or pancreatitis that may contribute to ulcer formation.

Step 3: Evaluate for Complications Assess for complications that may prevent healing. Repeat abdominal imaging to evaluate for perforation, abscess formation, or gastric outflow obstruction. Consider repeat endoscopy with biopsy to evaluate for neoplasia if initial biopsies were nondiagnostic.

Step 4: Consider Alternative or Adjunctive Therapy If acid suppression appears inadequate, consider increasing omeprazole dose or switching to a different proton pump inhibitor. Add misoprostol if not already prescribed. Consider intravenous pantoprazole for patients unable to absorb oral medications. Evaluate the need for blood transfusion if anemia persists.

Step 5: Refer for Specialist Evaluation If no improvement occurs after 7 to 10 days of appropriate therapy, refer to a veterinary internal medicine specialist for further evaluation. Specialized diagnostic tests such as gastrin measurement, computed tomography, or advanced endoscopic techniques may identify previously unrecognized causes.

Common Failure Patterns and Corrective Actions

Pattern 1: Persistent Vomiting Despite Acid Suppression Possible causes include inadequate acid suppression, concurrent pancreatitis, gastric outflow obstruction, or drug intolerance. Corrective actions include verifying omeprazole administration timing, adding antiemetic therapy with maropitant, performing abdominal ultrasound to evaluate for obstruction, and considering alternative acid suppression medications.

Pattern 2: Continued Melena After 5 Days of Therapy Possible causes include ongoing hemorrhage from deep ulcer, undiagnosed coagulopathy, or concurrent lower gastrointestinal bleeding. Corrective actions include performing coagulation testing, repeating endoscopy to evaluate ulcer status, and considering surgical intervention for deep or bleeding ulcers.

Pattern 3: Recurrent Ulceration After Initial Healing Possible causes include intermittent NSAID administration by the owner, progression of underlying hepatic disease, development of gastrinoma, or undiagnosed mast cell disease. Corrective actions include thorough history review with the owner, serum gastrin measurement, abdominal ultrasound, and repeat endoscopy with biopsy.

Pattern 4: Weight Loss Despite Ulcer Healing Possible causes include underlying neoplasia, chronic gastritis, or concurrent pancreatic or intestinal disease. Corrective actions include complete dietary history, serum cobalamin and folate measurement, pancreatic lipase immunoreactivity testing, and full gastrointestinal endoscopy with biopsy.

Welfare and Safety Context

Gastric ulceration causes significant pain and distress in affected dogs. The condition impairs normal feeding behavior, leads to weight loss and debilitation, and can progress to life-threatening complications. Prompt recognition and appropriate management improve patient welfare outcomes.

Pain associated with gastric ulceration manifests as abdominal discomfort, reluctance to eat, and behavioral changes. Dogs may assume a hunched posture, show reluctance to move, or exhibit aggression when the abdomen is palpated. Adequate analgesia should be provided alongside acid suppression therapy.

The World Organisation for Animal Health emphasizes the importance of preventing and treating disease to maintain animal welfare. Veterinary professionals have an ethical obligation to provide appropriate diagnostic and therapeutic interventions for painful conditions such as gastric ulceration.

Owner education plays a critical role in ulcer prevention and management. Inform owners about the risks of NSAID administration, the importance of administering medications as prescribed, and the signs requiring veterinary attention. Provide written instructions for medication administration and follow-up care.

Records and Measurements

Maintain accurate medical records documenting all aspects of ulcer diagnosis and management. Include the following elements in the patient record.

Initial Assessment Documentation

• Presenting complaint and duration
• Complete medication history including NSAIDs, corticosteroids, and other drugs
• Physical examination findings with specific descriptions
• Initial laboratory results with reference ranges
• Imaging findings with interpretation
• Endoscopy findings with photographs and biopsy locations
• Histopathology results

Treatment Documentation

• Medication doses, routes, frequencies, and administration times
• Fluid therapy type, rate, and volume
• Blood transfusion details including product type, volume, and crossmatch results
• Surgical findings and procedure details
• Anesthesia records if applicable

Monitoring Documentation

• Daily clinical assessment parameters
• Serial laboratory results
• Body weight measurements
• Appetite and fecal character records
• Pain assessment scores

Outcome Documentation

• Ulcer healing status on repeat endoscopy
• Final diagnosis
• Long-term management plan
• Owner instructions provided
• Follow-up appointment schedule

Professional Escalation Criteria

Immediate Escalation to Emergency Facility Transfer to an emergency veterinary facility when:

• Active hemorrhage persists despite fluid resuscitation and medical management
• Packed cell volume continues to decline below 20% after blood transfusion
• Perforation is confirmed or strongly suspected based on clinical signs or imaging
• Cardiovascular instability develops despite appropriate fluid therapy
• Gastric dilation-volvulus is suspected concurrently

Escalation to Internal Medicine Specialist Refer to a veterinary internal medicine specialist when:

• Endoscopic equipment or expertise is not available in general practice
• Ulcers fail to heal after 14 to 21 days of appropriate therapy
• Underlying cause remains unidentified after thorough diagnostic evaluation
• Gastrinoma or other neuroendocrine tumor is suspected
• Complex hepatic disease requires specialized management

Escalation to Surgical Specialist Refer to a veterinary surgical specialist when:

• Surgical resection is required for large, deep, or neoplastic ulcers
• Gastric outflow obstruction develops
• Perforation requires emergency surgical repair
• Previous surgical intervention has failed

Escalation to Oncologist Refer to a veterinary oncologist when:

• Gastric neoplasia is confirmed on histopathology
• Mast cell tumor with visceral involvement is diagnosed
• Chemotherapy or radiation therapy is indicated
• Palliative therapy is needed for advanced disease

Practical Decision Framework for Canine Gastric Ulcer Management

Risk Stratification at Initial Presentation

A structured decision framework helps veterinarians triage patients based on clinical severity and underlying risk factors. This framework uses readily available clinical parameters to guide initial management decisions and escalation timing.

Low Risk Category Patients with mild clinical signs, stable vital parameters, and no evidence of active hemorrhage fall into the low risk category. Criteria include intermittent vomiting without visible blood, normal mucous membrane color, packed cell volume above 35%, and stable cardiovascular parameters. These patients may undergo diagnostic evaluation on an outpatient basis with close monitoring. Begin acid suppression therapy and schedule endoscopy within 24 to 48 hours.

Moderate Risk Category Patients with persistent vomiting, melena, or mild anemia (packed cell volume 25% to 35%) require hospitalization for initial stabilization. Administer intravenous fluids, begin acid suppression therapy, and perform diagnostic testing including complete blood count, serum biochemistry, and abdominal ultrasound. Schedule endoscopy within 12 to 24 hours depending on patient stability.

High Risk Category Patients with hematemesis, severe anemia (packed cell volume below 25%), hemodynamic instability, or suspected perforation require emergency stabilization. Establish intravenous access, administer crystalloid fluids, and prepare for blood transfusion if indicated. Perform abdominal imaging to evaluate for perforation. Emergency endoscopy or surgical exploration may be necessary based on patient response to initial therapy.

Treatment Algorithm Based on Etiology

The underlying cause of gastric ulceration directs specific management decisions beyond general acid suppression and mucosal protection.

NSAID-Induced Ulceration Algorithm Discontinue all NSAIDs immediately. Document the specific NSAID, dose, duration, and concurrent medications. Begin omeprazole at 1 mg/kg orally every 12 hours on an empty stomach. Add sucralfate at 0.5 to 1 gram orally every 8 to 12 hours, separated from omeprazole by at least two hours. Consider misoprostol at 2 to 5 mcg/kg orally every 8 to 12 hours with food if ulceration is severe or recurrent. Provide alternative analgesia using opioids or gabapentin. Schedule repeat endoscopy in 14 to 21 days to document healing.

Hepatic Disease-Associated Ulceration Algorithm Address the underlying hepatic condition concurrently with ulcer management. Begin omeprazole at 1 mg/kg orally every 12 hours. Add sucralfate for mucosal protection. Avoid medications requiring extensive hepatic metabolism when possible. Monitor liver enzymes, bilirubin, and albumin throughout treatment. Consider lactulose and dietary modification for hepatic encephalopathy if present. The prognosis depends on hepatic disease severity and response to therapy.

Neoplasia-Associated Ulceration Algorithm Obtain definitive histopathologic diagnosis through endoscopic biopsy. Begin omeprazole and sucralfate for symptomatic management. Consult with a veterinary oncologist regarding surgical resection, chemotherapy, or radiation therapy based on tumor type and stage. Surgical resection may be curative for localized gastric adenocarcinoma or leiomyosarcoma. Lymphoma may respond to chemotherapy with adjunctive acid suppression.

Stress-Related Ulceration Algorithm Address the underlying critical illness while providing gastric protection. Begin omeprazole intravenously if oral administration is not possible. Maintain adequate tissue perfusion through fluid therapy and vasopressor support if needed. Provide nutritional support through enteral feeding when gastrointestinal function permits. Monitor for signs of gastrointestinal bleeding including serial packed cell volume measurements and fecal occult blood testing.

Record System for Ulcer Monitoring

A standardized record system improves documentation consistency and facilitates treatment response assessment. Maintain the following parameters in the medical record.

Daily Monitoring Log Record the following parameters each day during hospitalization:

• Vomiting episodes: Number and character (blood, bile, food, foam)
• Fecal character: Color, consistency, frequency
• Appetite: Percentage of offered food consumed
• Packed cell volume and total solids
• Mucous membrane color
• Abdominal pain score (0 = none, 1 = mild on palpation, 2 = moderate, 3 = severe)
• Heart rate and respiratory rate
• Body weight

Medication Administration Record Document each medication dose, route, time, and any adverse effects. Note the timing of omeprazole administration relative to feeding. Record sucralfate administration times and separation from other oral medications.

Endoscopy Findings Documentation Create a standardized form for recording endoscopic findings including:

• Ulcer location using a gastric map diagram
• Number of ulcers
• Size in millimeters for each ulcer
• Depth classification (superficial erosion, deep ulcer, perforation)
• Appearance (clean base, adherent clot, visible vessel, active bleeding)
• Biopsy site locations
• Photographs of each ulcer

Treatment Response Assessment Evaluate treatment response at defined intervals:

• Day 3: Assess clinical improvement in vomiting, appetite, and fecal character
• Day 7: Repeat packed cell volume and serum biochemistry
• Day 14 to 21: Repeat endoscopy with biopsy to document healing
• Day 30: Final clinical assessment and long-term management plan

Troubleshooting Method for Poor Treatment Response

When patients fail to improve within 72 hours of initiating appropriate therapy, use the following systematic troubleshooting approach.

Step 1: Verify Medication Administration Confirm that the owner or hospital staff is administering medications correctly. Omeprazole requires administration on an empty stomach 30 to 60 minutes before feeding. Sucralfate must be separated from other oral medications by at least two hours. Misoprostol should be given with food to reduce gastrointestinal side effects. Check that doses are appropriate for the patient's current body weight.

Step 2: Reassess Underlying Cause Review the initial diagnostic findings for missed underlying causes. Consider additional testing including serum gastrin levels, abdominal ultrasound, or advanced imaging. Evaluate for concurrent diseases such as renal failure, hypoadrenocorticism, or pancreatitis that may contribute to ulcer formation.

Step 3: Evaluate for Complications Assess for complications that may prevent healing. Repeat abdominal imaging to evaluate for perforation, abscess formation, or gastric outflow obstruction. Consider repeat endoscopy with biopsy to evaluate for neoplasia if initial biopsies were nondiagnostic.

Step 4: Consider Alternative or Adjunctive Therapy If acid suppression appears inadequate, consider increasing omeprazole dose or switching to a different proton pump inhibitor. Add misoprostol if not already prescribed. Consider intravenous pantoprazole for patients unable to absorb oral medications. Evaluate the need for blood transfusion if anemia persists.

Step 5: Refer for Specialist Evaluation If no improvement occurs after 7 to 10 days of appropriate therapy, refer to a veterinary internal medicine specialist for further evaluation. Specialized diagnostic tests such as gastrin measurement, computed tomography, or advanced endoscopic techniques may identify previously unrecognized causes.

Common Failure Patterns and Corrective Actions

Pattern 1: Persistent Vomiting Despite Acid Suppression Possible causes include inadequate acid suppression, concurrent pancreatitis, gastric outflow obstruction, or drug intolerance. Corrective actions include verifying omeprazole administration timing, adding antiemetic therapy with maropitant, performing abdominal ultrasound to evaluate for obstruction, and considering alternative acid suppression medications.

Pattern 2: Continued Melena After 5 Days of Therapy Possible causes include ongoing hemorrhage from deep ulcer, undiagnosed coagulopathy, or concurrent lower gastrointestinal bleeding. Corrective actions include performing coagulation testing, repeating endoscopy to evaluate ulcer status, and considering surgical intervention for deep or bleeding ulcers.

Pattern 3: Recurrent Ulceration After Initial Healing Possible causes include intermittent NSAID administration by the owner, progression of underlying hepatic disease, development of gastrinoma, or undiagnosed mast cell disease. Corrective actions include thorough history review with the owner, serum gastrin measurement, abdominal ultrasound, and repeat endoscopy with biopsy.

Pattern 4: Weight Loss Despite Ulcer Healing Possible causes include underlying neoplasia, chronic gastritis, or concurrent pancreatic or intestinal disease. Corrective actions include complete dietary history, serum cobalamin and folate measurement, pancreatic lipase immunoreactivity testing, and full gastrointestinal endoscopy with biopsy.

Welfare and Safety Context

Gastric ulceration causes significant pain and distress in affected dogs. The condition impairs normal feeding behavior, leads to weight loss and debilitation, and can progress to life-threatening complications. Prompt recognition and appropriate management improve patient welfare outcomes.

Pain associated with gastric ulceration manifests as abdominal discomfort, reluctance to eat, and behavioral changes. Dogs may assume a hunched posture, show reluctance to move, or exhibit aggression when the abdomen is palpated. Adequate analgesia should be provided alongside acid suppression therapy.

The World Organisation for Animal Health emphasizes the importance of preventing and treating disease to maintain animal welfare. Veterinary professionals have an ethical obligation to provide appropriate diagnostic and therapeutic interventions for painful conditions such as gastric ulceration.

Owner education plays a critical role in ulcer prevention and management. Inform owners about the risks of NSAID administration, the importance of administering medications as prescribed, and the signs requiring veterinary attention. Provide written instructions for medication administration and follow-up care.

Records and Measurements

Maintain accurate medical records documenting all aspects of ulcer diagnosis and management. Include the following elements in the patient record.

Initial Assessment Documentation

• Presenting complaint and duration
• Complete medication history including NSAIDs, corticosteroids, and other drugs
• Physical examination findings with specific descriptions
• Initial laboratory results with reference ranges
• Imaging findings with interpretation
• Endoscopy findings with photographs and biopsy locations
• Histopathology results

Treatment Documentation

• Medication doses, routes, frequencies, and administration times
• Fluid therapy type, rate, and volume
• Blood transfusion details including product type, volume, and crossmatch results
• Surgical findings and procedure details
• Anesthesia records if applicable

Monitoring Documentation

• Daily clinical assessment parameters
• Serial laboratory results
• Body weight measurements
• Appetite and fecal character records
• Pain assessment scores

Outcome Documentation

• Ulcer healing status on repeat endoscopy
• Final diagnosis
• Long-term management plan
• Owner instructions provided
• Follow-up appointment schedule

Professional Escalation Criteria

Immediate Escalation to Emergency Facility Transfer to an emergency veterinary facility when:

• Active hemorrhage persists despite fluid resuscitation and medical management
• Packed cell volume continues to decline below 20% after blood transfusion
• Perforation is confirmed or strongly suspected based on clinical signs or imaging
• Cardiovascular instability develops despite appropriate fluid therapy
• Gastric dilation-volvulus is suspected concurrently

Escalation to Internal Medicine Specialist Refer to a veterinary internal medicine specialist when:

• Endoscopic equipment or expertise is not available in general practice
• Ulcers fail to heal after 14 to 21 days of appropriate therapy
• Underlying cause remains unidentified after thorough diagnostic evaluation
• Gastrinoma or other neuroendocrine tumor is suspected
• Complex hepatic disease requires specialized management

Escalation to Surgical Specialist Refer to a veterinary surgical specialist when:

• Surgical resection is required for large, deep, or neoplastic ulcers
• Gastric outflow obstruction develops
• Perforation requires emergency surgical repair
• Previous surgical intervention has failed

Escalation to Oncologist Refer to a veterinary oncologist when:

• Gastric neoplasia is confirmed on histopathology
• Mast cell tumor with visceral involvement is diagnosed
• Chemotherapy or radiation therapy is indicated
• Palliative therapy is needed for advanced disease

Frequently Asked Questions

What are the most common clinical signs of gastric ulceration in dogs?

The most common signs include vomiting (often with blood), melena, abdominal pain, anorexia, and weight loss. Some dogs show only subtle signs such as lethargy or decreased appetite. The severity of signs correlates with ulcer depth and location.

How is gastric ulceration diagnosed definitively?

Upper gastrointestinal endoscopy with biopsy provides definitive diagnosis. Endoscopy allows direct visualization of the ulcer and collection of tissue samples for histopathology. Fecal occult blood testing and abdominal ultrasound support the diagnosis but cannot confirm ulceration.

What is the role of fecal occult blood testing in diagnosis?

Fecal occult blood testing detects hemoglobin in feces when visible blood is absent. It supports the diagnosis of gastrointestinal bleeding but does not localize the source. Positive results require further investigation with endoscopy or imaging.

How long does it take for gastric ulcers to heal with medical therapy?

Most uncomplicated ulcers heal within 14 to 21 days of appropriate medical therapy. Repeat endoscopy at this time evaluates healing. Deep or large ulcers may require longer treatment. Persistent ulcers require investigation for underlying causes.

Can gastric ulcers recur after treatment?

Yes, recurrence is possible if the underlying cause persists. NSAID-induced ulcers may recur if NSAIDs are readministered. Ulcers associated with hepatic disease or neoplasia may recur if the primary condition is not controlled.

What dietary modifications are recommended for dogs with gastric ulcers?

Feed a bland, easily digestible diet in small, frequent meals. Low-fat diets reduce gastric emptying time and decrease bile reflux. Avoid high-protein diets that stimulate gastrin release and acid secretion. Commercial gastrointestinal diets are appropriate.

When is surgical intervention necessary for gastric ulcers?

Surgery is indicated for perforated ulcers, uncontrolled hemorrhage, gastric outflow obstruction, and neoplastic ulcers requiring resection. Deep ulcers at risk of perforation may also require surgical intervention.

What is the prognosis for dogs with gastric ulceration?

Prognosis depends on the underlying cause. NSAID-induced ulcers have a good prognosis when NSAIDs are discontinued and appropriate therapy is provided. Ulcers associated with hepatic disease or neoplasia have a guarded prognosis depending on the primary condition. Perforated ulcers carry a poor prognosis without emergency surgical intervention.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Dog Kidney Disease Diet
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Gastric disease in the dog and cat.. Veterinary journal (London, England : 1997), 1998.
• Barrett's esophagus.. Surgery, gynecology & obstetrics, 1983.
• Antiulcer therapy.. The Veterinary clinics of North America. Small animal practice, 1993.
• Acute hepatic failure.. The Veterinary clinics of North America. Small animal practice, 1985.
• Gastroscopic electrosurgery.. Gastroenterology, 1971.
• Gastric Intravascular Lymphoma in a Dog: Case Report and Literature Review.. Journal of the American Animal Hospital Association, 2020.
• Preparation and evaluation of a suppository dosage form containing omeprazole. Pharmaceutical Sciences, 1997.
• Effects of H2-receptor antagonists upon physiological acid secretory states in animals. Journal of Pharmacology and Experimental Therapeutics, 1985.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.